Professor, Department of Hematology and Medical Oncology, Department of Pharmacology and Chemical Biology, Emory University School of Medicine; Director, Phase I Clinical Trials Program, medical director, Clinical Trials Office, Winship Cancer Institute of Emory University
Department Chair ad interim, Waun Ki Hong Distinguished Chair, professor, Department of Experimental Therapeutics, Division of Cancer Medicine, faculty liaison, Division of Office of Postdoctoral Affairs and Development in Education & Training, MD Anderson Cancer Center
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
The day before health economist Jay Bhattacharya stepped into his new role as NIH director, he sent a document to his employees outlining his top five priorities for the department, which included “reproducibility” and “transparency,” two themes he discussed at his confirmation hearings (The Cancer Letter, March 7, 2025).
When I started this column, I was wanting to retain the sense of connection that I had to the greater cancer community as I stepped away into a period of disconnection.